Citigroup Inc Exelixis, Inc. Transaction History
Citigroup Inc
- $196 Billion
- Q2 2025
A detailed history of Citigroup Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Citigroup Inc holds 696,831 shares of EXEL stock, worth $27.9 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
696,831
Previous 465,031
49.85%
Holding current value
$27.9 Million
Previous $17.2 Million
78.91%
% of portfolio
0.02%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding EXEL
# of Institutions
688Shares Held
260MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.34 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$1.1 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$643 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$634 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$456 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...